SGMT vs. ZYME, PHAR, MLYS, PHAT, ORIC, ALXO, SVRA, CDMO, IGMS, and TRDA
Should you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Zymeworks (ZYME), Pharming Group (PHAR), Mineralys Therapeutics (MLYS), Phathom Pharmaceuticals (PHAT), ORIC Pharmaceuticals (ORIC), ALX Oncology (ALXO), Savara (SVRA), Avid Bioservices (CDMO), IGM Biosciences (IGMS), and Entrada Therapeutics (TRDA). These companies are all part of the "pharmaceutical preparations" industry.
Sagimet Biosciences (NASDAQ:SGMT) and Zymeworks (NYSE:ZYME) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
Sagimet Biosciences has higher earnings, but lower revenue than Zymeworks.
In the previous week, Sagimet Biosciences had 7 more articles in the media than Zymeworks. MarketBeat recorded 9 mentions for Sagimet Biosciences and 2 mentions for Zymeworks. Sagimet Biosciences' average media sentiment score of 0.86 beat Zymeworks' score of -0.66 indicating that Sagimet Biosciences is being referred to more favorably in the media.
87.9% of Sagimet Biosciences shares are owned by institutional investors. Comparatively, 92.9% of Zymeworks shares are owned by institutional investors. 17.6% of Sagimet Biosciences shares are owned by company insiders. Comparatively, 1.2% of Zymeworks shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Sagimet Biosciences currently has a consensus price target of $39.20, suggesting a potential upside of 616.64%. Zymeworks has a consensus price target of $12.67, suggesting a potential upside of 49.37%. Given Sagimet Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Zymeworks.
Zymeworks received 270 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 100.00% of users gave Sagimet Biosciences an outperform vote while only 68.59% of users gave Zymeworks an outperform vote.
Sagimet Biosciences has a net margin of 0.00% compared to Zymeworks' net margin of -249.63%. Zymeworks' return on equity of -28.37% beat Sagimet Biosciences' return on equity.
Summary
Sagimet Biosciences beats Zymeworks on 10 of the 15 factors compared between the two stocks.
Get Sagimet Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SGMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sagimet Biosciences Competitors List
Related Companies and Tools
